New Releases from NCBI BookshelfPembrolizumab (Keytruda): Indication: For the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high or mismatch repair deficient solid tumours, as determined by a validated test, that have progressed following prior treatment and who have no satisfactory alternative treatment options: Reimbursement Recommendation [Internet].​Pembrolizumab (Keytruda): Indication: For the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high or mismatch repair deficient solid tumours, as determined by a validated test, that have progressed following prior treatment and who have no satisfactory alternative treatment options: Reimbursement Recommendation [Internet].